ライフサイエンスコーパス: CVVHD

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 ences in clearance for IL-6 between CVVH and CVVHD did not translate into significant changes in circ

2 Amino acid loss on CVVH and CVVHD was similar (12.50+/-1.29 g/day/1.73 m2 vs. 11.61+

3 and 29.0+/-.97 mL/min/1.73 m2) for CVVH and CVVHD, respectively.

4 as performed on six patients during CVVH and CVVHD.

5 d with an ultrafiltration rate of 2 L/hr and CVVHD with a dialysis outflow rate of 2 L/hr.

6 CVVHD, 161 patients undergoing citrate-based CVVHD were screened for the presence of an elevated tota

7 ver failure patient undergoing citrate-based CVVHD with elevated serum total to ionized calcium ratio

8 o ionized calcium ratio during citrate-based CVVHD, 161 patients undergoing citrate-based CVVHD were

9 ing the mixed convection and diffusion-based CVVHD/F (2.7 +/- 1.9 mg/dL, N = 12; range, 0 to 6 mg/dL)

10 mg/kg/day during CVVH, and 245 mg/kg/day for CVVHD.

11 2 on CVVH and 7.59+/-2.79 mL/min/1.73 m2 for CVVHD (NS).

12 between therapies, 1.9+/-0.8 (SD) mL/min for CVVHD and 3.3+/-1.5 mL/min for CVVH, (p< .01).

13 s venovenous hemodialysis/hemodiafiltration (CVVHD/F).

14 ith continuous venovenous hemodiafiltration (CVVHD).

15 Use of continuous veno-venous hemodialysis (CVVHD) for RRT has been reported in three series of OLTX

16 used for continuous venovenous hemodialysis (CVVHD) to minimize the risk of bleeding complications.

17 ort with continuous venovenous hemodialysis (CVVHD).

18 maintain nitrogen balance similar to that of CVVHD.

19 /1.73 m2 to a positive 5.50 g/day/1.73 m2 on CVVHD.

20 Clearance of AA is greater on CVVH than on CVVHD, but no significant difference in AA loss was pres

21 ations compared with a 23% increase while on CVVHD (p < .05).

22 vs. 50% in those patients who only received CVVHD postoperatively.

23 However, patients receiving CVVHD both pre- and postoperatively had a 90-day mortali

24 highest being present in patients receiving CVVHD, which was started postoperatively.

25 after VAD placement, and all three required CVVHD until death.

26 ratio occurs commonly in patients requiring CVVHD using citrate-based regional anticoagulation.

27 ance using CVVH or diffusive clearance using CVVHD for the first 24 hrs, followed by the other modali

28 ma TNF-alpha concentrations as compared with CVVHD, while the type of transport mechanism used did no

29 Patients treated with CVVHD had a 90-day mortality of 42% compared with 25% in

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。